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SUMMARY
New genetic investigation techniques, including next-generation sequencing, epige-
netic profiling, cell lineage mapping, targeted genetic manipulation of specific neuro-
nal cell types, stem cell reprogramming, and optogenetic manipulations within
epileptic networks are progressively unraveling the mysteries of epileptogenesis and
ictogenesis. These techniques have opened new avenues to discover the molecular
basis of epileptogenesis and to study the physiologic effects of mutations in epilepsy-
associated genes on a multilayer level, from cells to circuits. This manuscript reviews
recently published applications of these new genetic technologies in the study of epi-
lepsy, as well as work presented by the authors at the genetic session of the XII
Workshop on the Neurobiology of Epilepsy (WONOEP 2013) in Quebec, Canada.
Next-generation sequencing is providing investigators with an unbiased means to
assess the molecular causes of sporadic forms of epilepsy and has revealed the com-
plexity and genetic heterogeneity of sporadic epilepsy disorders. To assess the func-
tional impact of mutations in these newly identified genes on specific neuronal cell
types during brain development, new modeling strategies in animals, including condi-
tional genetics in mice and in utero knock-down approaches, are enabling functional
validation with exquisite cell-type and temporal specificity. In addition, optogenetics,
using cell-type–specific Cre recombinase driver lines, is enabling investigators to dis-
sect networks involved in epilepsy. In addition, genetically encoded cell-type labeling
is providing new means to assess the role of the nonneuronal components of epileptic
networks such as glial cells. Furthermore, beyond its role in revealing coding variants
involved in epileptogenesis, next-generation sequencing can be used to assess the epi-
genetic modifications that lead to sustained network hyperexcitability in epilepsy,
including methylation changes in gene promoters and noncoding ribonucleic acid
(RNA) involved in modifying gene expression following seizures. In addition, geneti-
cally based bioluminescent reporters are providing new opportunities to assess neu-
ronal activity and neurotransmitter levels both in vitro and in vivo in the context of
epilepsy. Finally, genetically rederived neurons generated from patient induced pluri-
potent stem cells and genetically modified zebrafish have become high-throughput
means to investigate disease mechanisms and potential new therapies. Genetics has
changed the field of epilepsy research considerably, and is paving the way for better
diagnosis and therapies for patients with epilepsy.
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Recent advances in genetic investigation techniques have
considerably enhanced our ability to analyze the molecular
pathways involved in epileptogenesis, as well as to dissect
the neuronal networks participating in seizure generation
with great cellular and temporal precision. These tech-
niques, including next-generation sequencing, epigenetic
profiling, cell lineage mapping, targeted genetic manipula-
tion of specific neuronal cell types, stem cell reprogram-
ming, and optogenetic manipulations within epileptic
networks, are progressively unraveling the mysteries of
epileptogenesis and ictogenesis. The power of these genetic
techniques in epilepsy research will be illustrated with
selected examples from recent publications and presenta-
tions at the XII Workshop on the Neurobiology of Epilepsy
(WONEP) 2013 meeting held in L’Esterel, Quebec, Can-
ada.
Next-Generation Sequencing in
Epilepsy: Gene Discovery
Next-generation sequencing has recently emerged as a
powerful and unbiased method to investigate the genetic
basis of rare and genetically heterogeneous sporadic epi-
lepsies not amenable to traditional genetic investigation
techniques. Traditional approaches, such as linkage analy-
sis and targeted sequencing of genes within specific meta-
bolic pathways, required large kindreds of affected
individuals. These approaches have been instrumental in
identifying genes involved in certain forms of autosomal
dominant forms of epilepsy, such as generalized epilepsy
with febrile seizures plus (GEFS+: SCN1A, GABRD),
juvenile myoclonic epilepsy (JME: GABRA1, CACNB4),
benign familial neonatal seizures (BFNS: KCNQ2,
KCNQ3), autosomal dominant nocturnal frontal lobe epi-
lepsy (ADNFLE: CHRNA4, CHRNB2, CHRNA2), and rare
recessive forms of epilepsy (Unverricht-Lundborg and
CSTB mutations, glucose transporter 1 (GLUT1) defi-
ciency and generalized epilepsy associated with SLC2A1
mutations, pyridoxal-dependant epilepsy due to PNPO
mutations, and so on) to name only a few examples. How-
ever, these techniques were poorly suited to the investiga-
tion of rare genetically heterogeneous disorders such as
the sporadic epileptic encephalopathies in which only one
affected proband is identified per family.
Molecular karyotyping approaches, such as array com-
parative genomic hybridization (aCGH) techniques, have
been informative in identifying common copy number
variants (CNVs) associated with various forms of epilepsy
including epileptic encephalopathies (reviewed in Mulley
and Mefford1) (Fig. 1). Indeed, pathogenic CNVs can be
identified in 10–15% of patients with severe early onset
epileptic encephalopathies (reviewed in Mulley and Mef-
ford1). The identification of rare and recurrent CNVs in
epilepsy led to the identification of new epileptic enceph-
alopathy genes included in these genomic intervals such
as PCDH19,2 CDKL5,3 STXBP1,4 GRIN2A,5 and CAC-
NA1A.6 Recent studies demonstrate that targeted rese-
quencing of some of these well-documented epilepsy
genes identifies a molecular diagnosis in approximately
10% of patients with epileptic encephalopathies.7 None-
theless, a majority of patients with epileptic encephalopa-
thies remain without an identifiable molecular etiology.
Next-generation sequencing techniques, such as whole-
exome and whole-genome sequencing, are now providing
unique opportunities to identify new epilepsy genes in unex-
plained cases of epileptic encephalopathies. Recent publica-
tions using whole-exome sequencing (see Fig. 2) have
identified de novo mutations in a variety of genes in a large
fraction of patients with sporadic epileptic encephalopa-
thies.8–10 These studies demonstrate the great genetic heter-
ogeneity of these disorders, with recurrent mutations
occurring in only a minority of identified genes. For
instance, a recent large-scale genetic study led by the Gene
Discovery in 4000 Epilepsy Genomes (EPI4K) consortium
uncovered 329 de novo mutations in 320 genes in a cohort
of 264 patients with epileptic encephalopathies, with only 9
genes carrying mutations in at least two probands.8 It is dif-
ficult to predict which of these genes are truly involved in
the pathogenesis of epileptic encephalopathies when private
mutations are identified in isolated cases. However, genes
with recurrent de novo mutations in patients with similar
clinical phenotypes are good candidates for future biologic
validation. Whole-exome sequencing has been particularly
powerful in identifying new genes with recurrent mutations
in selected clinical epilepsy disorders with strictly defined
clinical criteria, such as migrating partial epilepsy of
infancy (KCNT111), Ohtahara syndrome (CASK,12
KCNQ213), rolandic epilepsy (RBFOX1, RBFOX314), and
so on. Furthermore, exome sequencing studies have
expanded the phenotypic spectrum associated with some of
the well-known epilepsy genes. For instance, KNCQ2muta-
tions initially associated with benign familial myoclonic
epilepsy15 were subsequently associated with severe epilep-
tic encephalopathy and spasticity.16
Therefore, the emergence of different genetic
investigation techniques in recent years have led to the
identification of a multitude of new confirmed or putative
epilepsy candidate genes. However, in a majority of
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cases, the molecular, cellular, and physiologic conse-
quences of these mutations and the mechanisms by which
they cause epilepsy remain largely unknown. New genetic
techniques now offer great opportunities to study the cel-
lular and network consequences of these mutations in
vivo in new animal models.
A
B
Figure 1.
Comparative genomic hybridization (CGH) assays frequently reveal copy number variants (CNVs) in patients with unexplained epileptic
encephalopathy. (A) Comparative Genomic Hybridization (CGH) assays are conducted by comparing a patient’s genomic DNA, labeled
with a fluorescent dye such as fluorescein (green), to a control DNA, labeled with another fluorescent dye such as rhodamine (red), both
applied on a microarray chip in which each well contains a probe specific for a given genomic interval. Deletions (red) and amplifications
(green) in the proband’s DNA can be differentiated from areas with balanced (normal) DNA. The sensitivity of CGH analysis is inversely
proportional to the spacing of consecutive probes, usually around 500 Kb. (B) Examples of microdeletions (red) and microduplications
(blue) presenting with neurodevelopmental phenotypes and reported in the Angelman’s syndrome interval 15q11-13, encompassing the
UBE3A gene (generated using the UCSC Genome Browser on March 17, 2014).
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Mice Genetic Approaches to
Study the Cellular and
Network Mechanisms of
Epileptogenesis
As the genetic basis of several forms of epilepsy are
currently being unraveled, modeling of these mutations in
animals has become a prerequisite to delineating the cellu-
lar, molecular, physiologic, and network mechanisms
underlying epileptogenesis in these genetic forms of epi-
lepsy. Genetic models of epilepsy have long been used to
study network phenomena underlying particular forms of
epilepsy. For instance, many rodent models have been tradi-
tionally used to investigate the mechanisms underlying
spike-wave absence seizures, including mice carrying spon-
taneous mutations in different calcium channel genes, as
reviewed in Burgess and Noebels17 (Cacna1atg/tg, Cac-
na1atg-rol/tg-rol, Cacnb4lh/lh, Cacng2stg/stg, and so on) or rat
A B
Figure 2.
Whole exome sequencing often reveals detrimental de novo mutations in patients with sporadic epileptic encephalopathies. (A) Sche-
matic representation of the procedure involved in conducting whole exome sequencing. The proband’s genomic DNA is first sheared in
200 bp fragments, which are protected with end-adaptors. Second, the patient’s DNA is hybridized to an exome capture library con-
sisting of specific probes designed to recognize most coding fragments of human DNA (i.e., exons and adjacent intron–exon splice-site
junctions). The hybridized fragments are extracted using systems such as streptavidin-labeled beads. The patient’s exonic DNA is then
retrieved and sent for sequencing (massive parallel sequencing). (B) The sequences obtained are aligned to the reference human genome
sequence. Multiple reads will be obtained for each genomic interval sequenced. De novo variants that are unique to the proband and not
inherited from the parents can be identified. These variants are then confirmed using Sanger resequencing (illustrated in bottom panel). In
this particular patient presenting with early onset epileptic encephalopathy, exome sequencing revealed a single de novo variant, where
an A replaces the reference G in a heterozygous fashion (c. G875A), in the well-known epileptic encephalopathy gene STXBP1. This vari-
ant was predicted pathogenic by different bioinformatic scores, such as SIFT and PolyPHEN, which consider the variant’s impact on pro-
tein structure and domain conservation.
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strains carrying multigenic variants (GAERS andWAG/rij).
Furthermore, genetically engineered mice strains carrying
targeted mutations of human epilepsy genes have been par-
ticularly useful in studying various cellular and network
mechanisms leading to epilepsy (e.g., Arx,18,19 Scn1a,20
Scn8a, and Scn9a as phenotypic modifiers21,22). However,
these animal models did not provide cellular specificity and
could not be used to specifically address the cell-autono-
mous consequences of specific genetic mutations.
Conditional genetics to assess the cellular and network
consequences of epilepsy-associated mutations in
specific neuronal populations
Although traditional knockout (KO) models represent
good proxies for genomic mutations found in humans, they
do not permit the selective assessment of the cell-autono-
mous consequences of such mutations in particular cell-
types and their relevance to the overall clinical phenotype.
For instance, various anomalies have been identified in con-
stitutive Cacna1a and Cacnb4 mutants with spike-wave
absence seizures, including reduced cortical feed-forward
inhibition,23 reduced thalamic excitatory currents,24 tha-
lamocortical hyperexcitability due to upregulation of tha-
lamic low-threshold calcium currents,25 and gain of
aberrant thalamic tonic c-aminobutyric acid (GABA)ergic
currents.26 However, the contribution of these phenomena
to the overall epileptic phenotype was uncertain. Further-
more, investigators have shown that preventing thalamic
Cav3.1 upregulation, by crossing the Cacna1 g/ mutant
mice with the Cacna1a/ mice, prevents spike-wave sei-
zures, suggesting that low-threshold T-type calcium current
upregulation may not be necessary for the hypersynchroni-
zation underlying absence seizures in Cacna1amutants.
To dissect the impact of Cacna1a loss-of-function muta-
tions on different components of the thalamocortical cir-
cuitry involved in generating spike-wave seizures,
Rossignol et al.27 used a conditional genetic strategy to
selectively ablate Cacna1a in specific subsets of cortical
GABAergic interneurons or in cortical pyramidal cells,
while sparing thalamic neurons (Fig. 3). The targeted loss
of Cacna1a in medial ganglionic eminence (MGE) derived
neocortical and hippocampal GABAergic interneurons
(Nkx2.1Cre; Cacna1ac/c) leads to a severe form of general-
ized epilepsy in mice. Furthermore, Rossignol et al.27 dem-
onstrated that this mutation selectively impaired GABA
release from parvalbumin-positive fast-spiking basket-cells,
leading to unreliable transmission with high failure rates and
perturbed kinetics (Fig. 3). By contrast, the loss of Cacna1a
in the somatostatin-positive neuronal population was effi-
ciently compensated by upregulation of N-type calcium
channels, which preserved neurotransmission from these
cells, as demonstrated through optogenetic stimulation of
this population in SSTCre; Cacna1ac/c mice injected with a
Cre-dependant AAV-ChR2 virus. Finally, it was demon-
strated that the generalized spike-wave seizures observed in
the Nkx2.1Cre; Cacna1ac/c mutants did not involve the up-
regulation of thalamic calcium T-type currents. However,
the additional ablation of Cacna1a in cortical pyramidal
cells (Nkx2.1Cre; Emx1Cre; Cacna1ac/c) considerably less-
ened the seizure severity, leading to isolated absence sei-
zures by reducing cortical excitability in the face of cortical
inhibitory dysfunction.27 This study by Rossignol et al.,
therefore, demonstrates the usefulness of targeted genetic
modifications of specific neuronal cell types within epileptic
networks to clarify the basic mechanisms underlying epile-
ptogenesis and to study the cell-type specific consequences
of particular mutations in genetic forms of epilepsy.
This study further supported recent work by many groups
highlighting the role of GABAergic interneuron dysfunc-
tion in epilepsy (reviewed in Rossignol28). Similar condi-
tional genetic approaches revealed GABAergic interneuron
dysfunctions in Dravet-associated Scn1a mutations,29 as
well as in Rett-syndrome associated Mecp2 mutations.30
Furthermore, genetic studies in mutant mice carrying tar-
geted deletions in genes involved in cortical GABAergic
interneuron specification, migration, and maturation (Dlx5/
6, Dlx1/2, Nkx2.1, Lhx6, Sox6, Sip1) have been shown to
result in epilepsy in mice and might be involved in rare
forms of epilepsy in humans (as reviewed in Rossignol28).
Together, these studies highlight the importance of specific
subsets of GABAergic interneurons in preventing seizures
within neuronal circuits and support the idea of cell-based
therapies in specific forms of epilepsy associated with
GABAergic interneuron dysfunction.
Gene repression via in utero electroporation to study the
early developmental consequences of specific mutations
during embryogenesis
Generating new mice lines to study the impact of particu-
lar mutations on neuronal development can be time-con-
suming and expensive. To accelerate the process of
functional validation of newly identified epilepsy genes,
knockdown approaches using micro (mi)RNA and short
hairpin (sh)RNA are increasingly being used. These
approaches must be carefully controlled, as nonspecific
effects can occur and can bias the interpretation of findings.
For instance, an shRNA targeting a specific channel could
result in unexpected cellular findings due to its nonspecific
effects on other genetically related ionic channels. There-
fore, it is customary to combine knockdown experiments
with rescue experiments using shRNA-resistant plasmids to
confirm the specificity of these findings. When carefully
conducted, experiments using knockdown strategies enable
rapid screening of different genes identified through clinical
studies, with great spatial and temporal precision. For
instance, genetic repression of the Dravet-associated Scn1a
gene within septal neuronal populations recently allowed
investigators to study the role of this gene in septal GAB-
Aergic neurons governing their regulation of hippocampal
theta rhythms during cognitive tasks.31
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The delivery of experimental and scramble control
shRNA to neuronal cell types can be achieved using viral
vectors (i.e., AAV, lentiviruses, etc), which will ensure
widespread expression within neuronal populations in a
given location, with high temporal and spatial resolution.
Although these viral-based strategies offer good recombina-
tion capabilities, they are difficult to titrate to smaller cell
numbers in order to address cell-autonomous phenotypes
without affecting the global environment. Furthermore,
these strategies cannot be use to study the impact of particu-
lar mutations in early embryonic processes, such as neuro-
nal migration, due to the delay of expression of virally
transfected plasmids. For such purposes, in utero electropo-
rations offer greater flexibility with genetic repression
observed within 24–48 h, compared to the usual 1–2 weeks
required for virus-based recombination. In utero electropo-
ration offers significant advantages over traditional KO
approaches to study the cell-autonomous consequences of
mutations in disease-associated genes at a cell-specific level
during brain development.32 For instance, this mosaic
genetic approach offers unique opportunities to study the
role of specific cytoskeletal molecules on neuronal migra-
tion as a fundamental process of neurodevelopment dis-
rupted in epileptogenesis. Such shRNA-based approaches
using in utero electroporations have been used widely to
study the molecular mechanisms regulating neuronal migra-
tion. For instance, deficits and/or rescue of cortical pyrami-
dal cell division and migration defects associated with Lis1,
Dcx, Dab2ip, Tubg1, Kif5C, and Kif2Amutations have been
demonstrated using in utero electroporations.33–36
Grisar et al. have used such approaches to study the role
of a new epilepsy gene. Heterozygous mutations in myoclo-
nin1/EFHC1 have recently been shown to co-segregate with
juvenile myoclonic epilepsy (JME) phenotypes. In adoles-
cent JME patients, these genetic alterations produce subtle
malformations of cortical and subcortical architecture,
whereas homozygous F229L mutation in infancy induces
severe brain pathology and death. However, the underlying
pathologic mechanisms for these observations remain
unknown. Grisar et al. first demonstrated that EFHC1 is a
microtubule-associated protein (MAP) involved in cell divi-
sion and radial migration during cerebral corticogenesis.37
JME mutations, including F229L, do not alter the ability of
EF-hand domain (C-terminal) containing 1 (EFHC1) to
colocalize with the centrosome and the mitotic spindle but
act in a dominant-negative manner to impair mitotic spindle
organization.38 Using both in utero and ex vivo electropora-
tion technologies, Grisar et al. also found that mutant
EFHC1 expression disrupted radial and tangential migration
by affecting morphology of radial glia and migrating neu-
rons (Fig. 4).38 These results illustrate how myoclonin1/
EFHC1 mutations disrupt brain development, potentially
leading to structural brain abnormalities as a basis for epile-
ptogenesis.
Optogenetics to Dissect
Network Components in the
Epileptic Brain
The advent of optogenetics with its ability to selectively
modulate specific neuronal populations involved in epilep-
tic networks has provided unique opportunities to unravel
some of the basic mechanisms of seizure generation. These
techniques are taking advantage of recent advances in
genetic mouse engineering and neurobiology to enable sci-
entists to selectively modulate different components of epi-
leptic networks, as briefly illustrated here. Recent advances
in our understanding of the genetic determinants controlling
the specification of various subsets of GABAergic interneu-
rons (reviewed in Rossignol28), led to the generation of
selective Cre-recombinase mouse driver lines39 that can
now be used to selectively modulate neuronal activity using
optogenetic approaches. The use of Cre-dependant adeno-
associated virus (AAV)-based viral vectors to selectively
express opsins (ChR2, Arch, and so on) in specific neuronal
populations allows the dissection of neuronal networks
involved in epilepsy and the study of the cell-type specific
impact of particular genetic mutations. For instance, using
cell-type specific green fluorescent protein (GFP) expres-
sion in somatostatin-positive GABAergic interneurons
(GINEGFP mouse), researchers recently identified cortical
GABAergic network reorganization leading to somato-
statin-cell sprouting in the hippocampus of pilocarpine-
exposed mice.40 Furthermore, by using ChR2 expressed
selectively in these cells, this sprouting was demonstrated to
be biologically relevant, as the cells form functional syn-
apses onto neighboring projection neurons.40 Optogenetic
approaches also enabled the precise dissection of corticotha-
lamic networks involved in seizure generation following
focal cortical strokes and illustrated that the silencing of
ventrobasal thalamocortical projection neurons can be used
to abort cortically induced seizures using a closed-loop
approach.41 Closed-loop interruption of seizures can also be
achieved by optogenetic silencing of excitatory neurons or
optogenetic activation of parvalbumin-positive basket cells
in temporal lobe epilepsy models.42
Nonneuronal Populations
Contribute Extensively to
Network Homeostasis: Role of
Neuroglial Interactions and
Microglia in Epilepsy
Emerging evidence has revealed the fundamental roles
of glial cells, and particularly astrocytes, in regulating neu-
ronal excitability and synaptic transmission.43 The ability
to visualize these glial populations through targeted
genetic labeling, as well as to monitor their activity in neu-
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ronal circuits through targeted calcium imaging,44 both in
vitro and in vivo, has revealed the primary role of these
cells in cortical circuits. In the context of epilepsy, glial
cells have been shown to regulate glutamate levels and to
restrain cortical excitability.45 Furthermore, astrocytes
have been shown to regulate neurovascular coupling,46
which is sometimes perturbed in the context of metabolic
failure or hyperlactatemia within damaged or chronically
hyperexcitable tissues.
Microglia have also been recently implicated in the path-
ophysiology of chronic epilepsy. Indeed, temporal lobe epi-
lepsy (TLE) is characterized not only by hippocampal
A
B C
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neuronal cell death and reactive astrogliosis, but also by the
presence of activated microglia,47 which is thought to be
detrimental for neuronal survival. However, recent findings
suggest that microglia display neuroprotective properties in
various central nervous system (CNS) pathologic condi-
tions. Vinet et al. determined the effect of microglia deple-
tion on excitotoxicity-induced neurodegeneration using
mouse organotypic hippocampal slice cultures. Treatment
of slice cultures with 10–50 lM N-methyl-D-aspartate
(NMDA) induced a region specific increase in neuronal cell
death, with CA1 neurons being most vulnerable to NMDA
exposure, followed by CA3 and DG neurons, respectively.48
This selective neuronal vulnerability strongly correlated
with activation of local microglia. Ablation of microglia by
treatment of slice cultures with liposome-encapsulated
clodronate, and subsequent exposure to NMDA, resulted in
severely enhanced neuronal cell death in the CA3 and DG
region. Replenishment of microglia-free slices with micro-
glia restored the original resistance of CA3 and DG neurons
toward NMDA. These data suggest that ramified microglia
contribute to the protection of neurons under excitotoxic
conditions and that activated microglia might serve to
remove dead neuronal debris by phagocytosis. Thus, to bet-
ter understand the role of microglia in TLE, Vinet et al. are
acutely isolating microglia from the hippocampi of pilocar-
pine-treated animals. For this purpose, antibodies raised
against specific membrane proteins are used to discriminate
microglia from infiltrating macrophages through fluores-
cence-activated cell sorting (FACS) sorting. This enables
further experiments of specific genetic determinants of acti-
vated microglia by analyzing the transcriptional and proteo-
mic profile of these cells using a combination of
quantitative polymerase chain reaction (qPCR) andWestern
blotting, focusing on a set of markers involved in inflamma-
tory processes and cell survival.49 This approach has been
used successfully in animal models of neurologic disease,
Figure 4.
Invalidating myoclonin1 disrupts radial neuronal migration. Down-regulation of myoclonin1 using an shRNA delivered through in utero
electroporation reveals a substantial impairment in neuronal migration and confirms the role of this gene in cortical development (CP:
Cortical plate, IZ: intermediate zone, VZ/SVZ: [sub]ventricular zone).37
Epilepsia ILAE
Figure 3.
Conditional genetic strategies to generate mutant mice carrying cell-type selective mutations. (A) Conditional genetic strategies allow
the generation of mutant mice carrying a specific loss-of-function mutation in a gene of interest in a cell-type and tissue-specific manner.
Driver mouse lines are selected based on their expression of Cre recombinase driven by promoters expressed selectively in the cell types
and tissues of interest. This line is then bred on a conditional mutant mouse line carrying a floxed allele of the gene of interest, in which
Lox P sites have been inserted around specific exons. The floxed allele is expressed properly in all tissues except in cells that express the
Cre recombinase. In these mutated cells, the lox P sites will be recombined, effectively generating a deletion between the two sites, often
leading to a loss-of-function allele. A conditional reporter mouse line can be bred unto these mutants, allowing for the specific labeling of
cells expressing the Cre recombinase. The mutated cells can then be tracked in a reliable fashion for their entire life-time as enhanced
green fluorescent protein (EGFP) will be expressed stably over time. In the example illustrated here, an Nkx2.1Cre driver line was used to
selectively ablate the fourth exon of the Cacna1a gene, leading to a loss-of-function allele. (B) The Nkx2.1Cre line was selected as it effi-
ciently recombines the majority of cortical and limbic GABAergic interneurons derived from the medial ganglionic eminence, including
the parvalbumin (PV) and the somatostatin (SST) expressing populations, while sparing the GABAergic cell populations in the thalamus
reticular nucleus (RN). (C) Mutant cells can then be assessed using a variety of techniques, such as immunohistochemistry and in vitro
physiology. In the example illustrated here, paired recordings between cortical fast-spiking (FS) GABAergic interneurons (identified using
the RCEEGFP conditional labeling) and connected pyramidal cells revealed a significant alteration in the synaptic release properties of
mutated FS interneurons in conditional Nkx2.1Cre; Cacna1ac/c; RCEEGFP mutant mice compared to littermate controls. These conditional
mutants developed severe early onset generalized seizures (adapted from Rossignol et al.27).
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such as multiple sclerosis.50 Moreover, such approaches
have been optimized for human tissue.51 Such approaches
could therefore eventually be used in human biopsy speci-
mens of patients with pharmacoresistant TLE to further
evaluate the role of microglia in chronic epilepsy.
Epigenetic Modifications in
Epilepsy
Beyond genomic mutations, epigenetic modifications are
known to contribute to disease states in chronic neurologic
disorders, including in epilepsy. For instance, in various ani-
mal models of epilepsy, including the status-induced epi-
lepsy, the pharmacologically induced chronic epilepsies
(pilocarpine, kainate, and so on) and in genetic models of
epilepsy, circuits exposed to chronic hyperactivity have
been shown to undergo epigenetic modifications that con-
siderably alter neuronal excitability and further aggravate
the seizure phenotype. For instance, decreased hyperpolari-
zation-activated cyclic nucelotide-gated (HCN) channels
(reviewed in Poolos52), reorganized GABAA receptor su-
bunits (reviewed in Grabenstatter et al.53), and aberrant
tonic GABA currents54 have all been shown to maintain an
hyperexcitable state in models of chronic epilepsy. Many
more epigenetic modifications are likely to take place in
chronically hyperactive networks. The recent advances in
massive parallel sequencing technologies coupled with
improved molecular and computational techniques55 now
allow researchers to profile the entire transcriptome, gen-
ome, targeted exome, as well as all different layers of the
epigenome at very high resolutions.56
Study of the “methylome” in epilepsy
Taking advantage of these new technologies to assess
potential epigenetic changes in known and unknown genes
in an unbiased fashion, Kobow et al. used a massive parallel
sequencing approach to map genome-wide alterations in
DNA methylation in a rat model of chronic TLE(Fig. 5).
Sequencing of messenger RNA (mRNA) was further used
in identical specimens for complementary gene expression
profiling and integration with methylome data.57 Unsuper-
vised clustering of an epigenetic mark, that is, DNAmethyl-
ation, separates epileptic from nonepileptic animals.
Furthermore, DNA methylation was found to be inversely
correlated with gene expression, suggesting that epigenetic
regulation of gene expression may be critical in epilepto-
genesis and in the maintenance of the chronic disease state.
Aberrant locus-specific DNA methylation may also be of
interest as a potential biomarker for early detection of dis-
ease onset, prognosis, or monitoring of disease after ther-
apy. These experiments therefore highlight multiple new
pathways of epigenetic mechanisms contributing to chronic
epilepsy. These results will be particularly important, as
some of these epigenetic modifications could possibly be
prevented by using selective medications aimed at control-
ling these epigenetic processes in patients with refractory
epilepsy, for instance by using valproate acid with its poten-
tial as an histone-deacetylases (HDAC) inhibitor. Such
approaches might be particularly important in cases where
the underlying molecular mechanism is one that affects epi-
genetic control of gene expression, such as with UBE3A
mutations in Angelman syndrome or MECP2 and CDKL5
mutations in Rett syndrome.
miRNA in epilepsy
miRNA are small endogenous noncoding RNAs that
exert crucial roles in regulating gene expression and particu-
lar genetic programs by regulating the expression of target
mRNAs at a posttranscription level (Fig. 6). To date, more
than 1,000 human miRNAs have been identified. Specific
miRNAs have recently been shown to regulate cell-fate
specification and brain development (reviewed in Sun et
al.58 and Petri et al.59). Of interest, mutations and polymor-
phisms involving selected miRNAs are increasingly being
associated with a variety of neuropsychiatric disorders,
including schizophrenia, Huntington’s disease, and Alzhei-
mer’s disease.60 miRNAs have also been shown to modify
transcript dynamics in a fundamental manner in epilepto-
genesis and to represent key target structures for new ther-
apy developments. Specifically, selected miRNAs are
involved in various cellular processes known to be dysregu-
lated in chronic epilepsy, including different deregulation of
cell death, neurogenesis, and synaptic plasticity.61 Thus,
understanding which specific miRNAs are differentially
expressed in epilepsy may help to identify some mecha-
nisms underlying the disease. Moreover, these miRNAs
may represent biomarkers with prognostic value that iden-
tify specific subpopulations of patients with epilepsy.
M. Simonato (unpublished data) examined the expression
of >1,000 human miRNAs in the dentate gyrus granular cell
layer of resected surgical specimens from 10 patients who
underwent surgery for intractable TLE. By profiling the
miRNA expressed in surgical specimens with or without
granule cell dispersion, Simonato et al. identified specific
miRNA expressed selectively in tissue with granule cell dis-
persion, and characterized the downstream targets of these
identified miRNAs. Given that granule cell dispersion is a
frequent pathologic hallmark in the hippocampus of TLE
patients,62 the identification of an miRNA signature can
improve our understanding of this pathogenetic process
with potential diagnostic and therapeutic implications.63
Neuroanatomic correlates of relative seizure disposition
and comorbid behavioral profiles: lessons from “FAST”
and “SLOW” rats
Epilepsy and autism spectrum disorder (ASD) share sev-
eral primary and comorbid symptoms, particularly when
acquired during childhood.64 Common traits often associ-
ated with both disorders include seizures, developmental
delay, hyperactivity, impulsivity, aggression, and intellec-
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tual impairment. Such extensive clinical overlap is believed
to signify a “spectrum of vulnerability” that arises from an
early common dysfunction in central nervous system devel-
opment.64
The seizure-prone (FAST) and seizure-resistant (SLOW)
rat strains represent an animal model to address respective
comorbidities. FAST and SLOW rat strains were derived
from parent populations of Long-Evans Hooded (LEH) and
Wistar rats, using selective breeding processes based on a
differential vulnerability to amygdala kindling.65 Remark-
ably, as kindling sensitivity increased over generations in
the FAST strain, additional traits evolved that are highly
reminiscent of those observed in ASD, including hyperac-
tivity, impulsivity, learning deficits, repetitive behaviors,
and delays in visuomotor and social development. Given
rising interest in the identification of neuroanatomic corre-
lates able to predict vulnerability toward these interrelated
disorders, Gilby et al. first used T2-weighted MRI to inves-
tigate any gross neuroanatomic differences that might exist
between these strains. MR tractography was then used to
Figure 5.
Analyzing epigenomic signatures in epilepsy using next-generation sequencing. Epigenetic marks can be analyzed on a genome level using
massive parallel sequencing technologies also referred to as next-generation sequencing (NGS). To study DNA methylation, preparation
of genomic DNA is required followed by a sonication step to fragment DNA (300–400 bp). Methylated DNA can then be enriched using
either 5-mC specific antibodies (i.e., methylated DNA immunoprecipitation, MeDIP) or methyl-binding domain (MBD) proteins. 5-mC
capture–associated NGS can identify genomic regions with medium to high 5-mC content. However, for methylation analysis down to
single base pair resolution, genomic bisulfite sequencing is required (not shown). Kobow et al. recently mapped global DNA methylation
patterns in a rat model of TLE. They provide the first report of unsupervised clustering of an epigenetic mark being used in epilepsy
research to separate epileptic from nonepileptic animals. NGS can also be combined with chromatin immunoprecipitation (ChIP) or
selective preparation methods for coding and noncoding RNAs (mRNA, microRNAs, long ncRNAs) to analyze histone modifications or
RNA-expression patterns respectively. Currently no such epigenomic data sets are available from human or experimental epilepsy tissue
(N/A).
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more closely examine differences in white matter tracts and
connectivity. Both imaging techniques demonstrated clear
differences in the brains of FAST versus SLOW rats, includ-
ing larger white matter and ventricular volumes in FAST
rats. These findings provide evidence of structural corre-
lates with the potential to serve as a biomarker for individu-
als that have a predisposition toward or against the seizure-
prone condition and associated comorbid behavioral traits.
The ability of these and other noninvasive imaging tech-
niques to identify individuals at risk is potentially of great
value for epilepsy and ASD, given that early intervention
has proven beneficial for both of these disorders. Given the
substantial relevance of genetic and epigenetic changes in
these animals,66 next-generation sequencing may eventu-
ally be applied to these models to identify the genetic modi-
fiers predisposing to different aspects of the comorbidities
observed. Furthermore, molecular imaging could be used in
these models subsequently.
Genetically Encoded In Vivo
Bioluminescent Reporters to
Study Neuronal Activity,
Excitability, Neurotransmitter
Homeostasis, and Specific
Promoter Activation in the
Context of Epilepsy
Neuronal activity monitoring via calcium imaging
Live imaging of neuronal activity via voltage sensor dyes
and genetically encoded calcium biosensors has gained
widespread popularity in the field of neuroscience, both in
vitro and in vivo.67 These techniques enable scientists to
image neuronal activity in a variety of contexts, for instance
to study the maturation of brain networks68 and identify the
generators of particular oscillatory activities during devel-
opment,69 to dissect the connectivity within given networks
when specific neuronal populations are activated,70 to study
the activation of specific networks or entire cortical col-
umns during task-related behavior,71,72 and to assess syn-
apses onto specific dendrites within three-dimensional (3D)
networks.73 In the field of epilepsy research, calcium imag-
ing has been used to monitor the propagation of epileptic
discharges within limbic74 and neocortical structures75,76
and to study the activation of various neuronal clusters77
and specific GABAergic interneurons75 during ictal dis-
charges.
Neuronal excitability monitoring via chloride imaging
Monitoring synaptic inhibition and intracellular chloride
homeostasis during network development has been made
possible by the generation of genetically encoded chloride
sensors.78 The use of such chloride sensors has revealed
pathologic deregulation of chloride homeostasis rendering
GABA paradoxically excitatory in disease conditions,
including in posttraumatic epilepsy,79 ischemia,80 and neo-
natal seizures.81
Neurotransmitter homeostasis monitoring via glutamate
biosensors
Recent advances have also made it possible to directly
monitor tissue levels of specific neurotransmitters in the
context of genetic epilepsy. For instance, glutamate excito-
toxicity is thought to contribute to the disease phenotype in
Rett syndrome (RTT). This disorder, most often caused by
Figure 6.
MicroRNA biogenesis and function. miRNA genes are transcribed
to generate primary miRNA (pri-miRNA) transcripts with a hairpin
secondary structure. Pri-miRNAs are cleaved by a multiprotein
complex that includes Drosha, generating pre-miRNAs that are
exported into the cytoplasm by Exportin 5. In the cytoplasm, Dicer
cleaves the hairpin loop, producing miRNA duplexes that are then
unwound to yield single-strand mature miRNAs. Finally, mature
miRNAs are incorporated into the RNA-induced silencing com-
plex (RISC) in a sequence of events involving several proteins,
including Argonaute proteins like Ago2. Once incorporated into
RISC, miRNAs guide the complex to specific mRNAs through
complementary base-pairing, leading to their cleavage or repres-
sion. Respective mechanisms appear to be active in epileptic brain
tissue.
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X-linked mutations in the MECP2 gene encoding the
methyl-CpG-binding protein 2,82 is often complicated by
epilepsy. Clinical studies show that early onset epilepsy
leads to a more rapid neurologic deterioration and a worse
prognosis in RTT patients.83 Abnormal EEG studies are
found in a 100% of RTT cases and are associated with
severe sleep dysfunction.84 RTT patients display higher glu-
tamate levels in their spinal fluid, and this excitotoxic state
has been proposed to underlie the regression and synaptic
dysfunction seen in this disorder.85
Mice with Mecp2 mutations show neuropathologic and
behavioral deficits similar to that reported for RTT patients.
Sophisticated EEG monitoring in mice is critical to deter-
mine the functional impact of genetic alterations on the
epileptic phenotype.86 To investigate the effects of sleep-
cycle dynamics on brain glutamate homeostasis in RTT,
Kadam et al. used 24 h video-EEG/electromyography
(EMG) recordings with synchronous in vivo cortical gluta-
mate biosensors in symptomatic Mecp2 KO mice (Fig. 7).
Spectral analysis on nonictal EEG studies correlated with
synchronous fluctuations in extracellular glutamate levels
in Mecp2 mutant mice as compared to controls. Intrigu-
ingly, significant dark-cycle specific biomarkers of signifi-
cant alterations in sleep macrostructure and microstructure
that resembled that of severe sleep deprivation were
observed. Absolute glutamate levels were significantly
higher in frontal cortices of KOs and the activity-dependent
homeostasis of glutamate was also severely impaired.
Therefore, similar to RTT patients,Mecp2KOmice showed
significant sleep-cycle dysfunction and the 24 h recordings
BA
DC
Figure 7.
Experimental design and biosensor glutamate specificity. (A) Schematics of biosensor that used a glutamate specific oxidative enzyme
reaction to detect every molecule of glutamate in extracellular space where implanted (image with permission from vendor website, Pin-
nacle Technologies Inc., Lawrence, KS, U.S.A.). (B) Schematic of location of stereotaxic implant to biosensor into frontal neocortex
(blue); placement of EEG leads (two recording and one reference) and mounting screw to anchor head mount to skull. (C) Representative
recording trace of the post experiment ex vivo calibration of glutamate biosensor shows specificity to glutamate (arrow heads). Step
readings for every 10 lM glutamate (three repeats) added to media were averaged for each sensor in the study (time scale bar = 1 min).
(D) Sensitivity of the glutamate biosensor in vivo was tested by injecting MK801 intraperitoneal injection (5 mg/kg), which elicited an
immediate (<1 min) and significant rise in the glutamate reading in the frontal cortex by the sensor. MK801, which is an NMDA receptor
antagonist is known to induce increases in endogenous glutamate levels (Wyckhuys et al.,102) and has been used to model various neuro-
logic disorders, such as epilepsy, schizophrenia, and Parkinson disease, where abnormal glutamate transmission is hypothesized to be
involved (Roenker et al.,103). Rapid increases in glutamate levels in the recorded trace after injection artifact (arrowhead) indicate potent
NMDA receptor block and potent sensitivity of biosensor in vivo (time scale bar = 5 min).
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identified biomarkers that underlie the progressive deterio-
ration and fatality in Mecp2 KO mice. Such biomarkers
might eventually be used to evaluate the rescue efficacy of
novel interventions in clinical practice. Similar approaches
to monitor specific neurotransmitter dynamics in disease
state (i.e., dopamine, serotonin) in conjunction with func-
tional imaging in humans have been widely used to assess
disease progression and response to treatment, for instance
in depression (reviewed in Hoflich et al.87). Biosensors for
glutamate and GABA are under development for clinical
use and could prove instructive in epilepsy.
In vivo monitoring of specific promoter activation:
calcium channel upregulation in chronic epilepsy
In vivo bioluminescence has so far been mainly used to
address dynamics of tumor growth. However, it also allows
the investigation of rapidly fluctuating molecular switches
occurring in epileptic brains. Status epilepticus (SE) induced
by pilocarpine in rodents causes a transformation of most
CA1 pyramidal cells from regular-firing to burst-firing
mode. By complementary electrophysiologic, pharmaco-
logic, and molecular approaches Becker and Yaari et al.
observed the underlying mechanism to be the specific tran-
scriptional upregulation of CaV3.2, a T-type Ca
2+ channel
pore-forming subunit, around day 3 after SE.88,89 This sub-
unit likely plays a key role in epileptogenesis, as its deletion
in mice substantially attenuates the development of sponta-
neous chronic seizure activity and the degeneration of hippo-
campal neurons normally induced by pilocarpine elicited SE.
Seizures occur spontaneously in the chronic epileptic
stage and seizure activity may have short-term influence on
the mRNA levels of CaV3.2. Therefore, an approach was
used that allows analysis of the CaV3.2 promoter activity as
surrogate marker of corresponding gene expression in living
mice, which monitored in parallel for spontaneous seizure
activity. In order to monitor and quantify CaV3.2 promoter
activity in a time wise manner in vivo, the CaV3.2 core pro-
moter (CaV3.2cp
90) was characterized and bioluminescence
imaging was applied (BLI; IVIS-Spectrum Optical In Vivo
Imaging System, Perkin Elmer, Waltham, MA, U.S.A.) on
mice injected in the hippocampus with recombinant adeno-
associated virus (rAAVs) harboring a luciferase reporter
gene under CaV3.2cp-control (Fig. 8). Using this approach,
specific CaV3.2cp hippocampal expression was observed,
indicating sufficient basal reporter gene activation and acti-
vation only in the epileptogenesis stage. This experimental
setup provides an intriguing tool to monitor the effects of
interfering with transcriptional control mechanisms in vivo
and correlate molecular genetic manipulation with behav-
ioral and semiologic consequences. The optimization of
reporter molecules and a potential switch to fluorescence
reporter molecules may be relevant in future approaches.91
Bioluminescence imaging can be used to repeatedly moni-
tor and quantify gene activity in the same animal and thus
can serve as an optimal tool to analyze the role of CaV3.2 in
the developing epileptogenic network at various stages of
epileptogenesis.
Systems Biology in the Study of
Epilepsy
The integration of the wealth of genetic information
obtained from tissue resected from patients with chronic
epilepsy, stemming from genomic mutations, to epigenetic
modifications, proteomics, and possible somatic mutations
requires the implementation of a system biology approach.
The easy availability of surgical specimens from patients
undergoing epilepsy surgery represents a unique prerequi-
site to integrate different genetic approaches to study dis-
eased tissues comprehensively on different molecular
levels. Integrated analyses of respective data may differenti-
ate between distinct pathogenetic aspects versus common
downstream pathways that can result from multiple brain
abnormalities in particular forms of epilepsy. Although a
wide variety of genetic and acquired histopathologic lesions
have been discovered, often no clear pathologic lesions are
seen in human epileptic neocortex resected for the treatment
A
B
Figure 8.
Imaging with in vivo bioluminescence probes reveal tissue-specific
activation of candidate genes following status epilepticus. (A) Rep-
resentative time course of an in vivo bioluminescence experiment
of promoter activation after brain insults. Initially, the virus harbor-
ing the promoter-bioluminescence reporter construct is injected
in relevant brain structures such as the hippocampus. Days later,
the first in vivo bioluminescence analysis (IVIS) is performed. The
insult, for example status epilepticus, is induced. Repetitive IVIS
analyses are following before the animal is killed for histology. (B)
Representative increased in vivo bioluminescence reflects
increased candidate promoter activity after SE.
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of intractable seizures. Loeb et al.92 have undertaken a sys-
tems biology approach to identify what is unique and what
features are shared among neocortical brain regions that
produce spontaneous spikes and/or seizures. Using a combi-
nation of functional genomics, proteomics, and metabolo-
mics, an online dataset and a multivariate interactome are
established that link all of these molecular features of the
tissue to electrical and clinical features of the disease.
Recently, Loeb et al. have used this platform to identify
differentially expressed genes in regions of seizure onset93
and regions showing high levels of interictal spiking.94 Of
interest, the lists of genes in these two groups are highly
overlapping, just as is seen electrophysiologically, where
regions of high interictal spiking are often the same regions
that generate seizures. Perhaps even more interesting, pat-
terns of gene expression became evident that are unique for
both spiking and seizures, with particular involvement of
components of the mitogen-activated protein kinase
(MAPK) pathway. These molecular studies have also pro-
duced a set of “tissue biomarkers” that can be used to stain
human epileptic cortex to identify the cellular populations
involved for both interictal spiking and seizures. Loeb et al.
found that in the case of interictal spiking, the most salient
pathways were all activated in superficial cortical layers
(I–III), suggesting that spiking may be generated from these
cortical layers. Consistently, an animal model of interictal
spiking that uses tetanus toxin in the somatosensory cortex
shows activation of these same neuronal lamina with the
same tissue biomarkers.95 Loeb et al. are also developing a
novel computational method to “predict” additional histo-
logic and molecular abnormalities shared by all patients
with neocortical epilepsy, regardless of the underlying
cause. These predictions in human neocortical tissues sug-
gest the existence of novel microlesions in deeper neocorti-
cal layers that is associated with segmental activation of
plasticity pathways in adjacent superficial layers. Taken
together, systems biologic studies of electrically mapped
human neocortex are powerful tools to hone in on common
pathways and specific laminar involvement in patients with
neocortical epilepsy and can be compared to many other
genetic and epigenetic approaches.
Toward Novel Therapies for
Specific Genetic Disorders:
Cell-Based Therapyand High-
Throughput Drug Screening
Stem cells: use of patient-derived iPS cells respecified
into neurons to study the biologic relevance of new
epilepsy mutations and possible avenues for stem cell
therapies
Although genetic modeling of specific mutations in
rodents has proved highly relevant to some aspects of
epilepsy research, it is time consuming and energy consum-
ing and is somewhat limited by interspecies differences.
Furthermore, the breath of new genetic findings in clinical
research will prevent quick modeling in mice, as the genera-
tion of a knock-in mouse takes many months, is consider-
ably expensive, and could not address the diversity of
mutations identified within any given gene. For these rea-
sons, modeling of human mutations in vitro using
genetically engineered neurons rederived from iPS cells
(induced pluripotent stem cells) obtained from skin fibro-
blasts of patients with epilepsy is a powerful emerging tech-
nology. Using these iPS rederivation techniques, scientists
are now able to generate specific subtypes of neurons carry-
ing the same mutation as that of the patient being investi-
gated. Using such technologies, scientists have recently
been able to study the impact of specific Dravet-associated
SCN1A mutations on neuronal excitability in neurons
obtained after rederivation of patient fibroblasts, shedding
new light on some of the mechanisms underlying the clini-
cal phenotypes in this genetic epilepsy.96
Furthermore, stem cell engineering is now offering
exciting prospects for new cell-based therapies for epi-
lepsy.97 Indeed, stem-cell–derived medial ganglionic emi-
nence progenitors of specific subtypes of GABAergic
interneurons, namely parvalbumin basket cells, have
recently been shown to migrate, disperse, mature, and inte-
grate properly in developing and mature networks in mice,
and to revert seizure and cognitive manifestations of differ-
ent genetic mutations.98,99 Furthermore, these transplanted
GABAergic progenitors have been shown to scale their
number and output in proportion to surrounding network
activity, such that no excessive inhibition results from
these transplanted cells.
iPS cells derived from human skin fibroblasts can be
genetically reprogrammed to acquire the properties of spe-
cific cell types, including GABAergic interneurons. Recent
advances in stem cell research have improved protocols to
generate higher numbers of particular cell types of interest
using human embryonic stem cells. Using a combination of
specific growth factors and genetic drivers, scientists have
been able to produce large amounts of neural cell types with
GABAergic neuron phenotypes.100 One can now hope that
such technologies, if applied to genetically engineered
MGE-type GABAergic interneurons rederived from human
skin iPS cells, could eventually lead to cell-based therapies
in selected cases of severe refractory epilepsies not amend-
able to epilepsy surgery or alternative therapies such as the
ketogenic diet or vagus nerve stimulator.
High throughput drug screening using nonmammalian
models: genetically modified zebrafish
Although stem cell approaches permit relatively high
throughput screening of the basic cellular mechanisms asso-
ciated with particular mutations, they cannot properly
address network phenomena or the clinical correlates of
specific therapies aimed at particular genetic mutations. For
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this purpose, investigators have recently designed high-
throughput strategies to genetically modify zebrafish, assess
the behavioral and electroencephalographic correlates of
given mutation and screen small-molecule libraries in
search for new antiepileptic treatments.101 Using a morpho-
lino-based Scn1a knock-down strategy in zebrafish, Bar-
aban et al. screened a library of 320 micromolecules and
identified clemizole as a potential new anticonvulsive medi-
cation. Such unbiased screening approach will likely iden-
tify many more potential therapeutic agents in the coming
years.
Conclusions
The new genetic investigation techniques that have
emerged in recent years have considerably advanced our
understanding of the molecular and epigenetic etiologies
underlying various forms of epilepsy in humans and have
provided unparalleled tools to dissect and study the impact
of these genes on various components of the neural circuits
involved in seizure generation. Furthermore, these new
techniques are now opening new avenues for the develop-
ment of novel therapeutic approaches in epilepsy.
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